57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients
Titel:
57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients
Auteur:
Tolosa Ortega, P. Cejalvo, J.M. Moragon Terencio, S. Carril-Ajuria, L. Bermejo, B. Ruiz, Á. Hernando Melia, C. Sánchez-Torre, A. Martínez, M.T. Herrera, M. Gambardella, V. Lema, L. Roda, D. Bernal, E. Rentero-Garrido, P. Lluch, A. Ciruelos, E.M. Cervantes, A. Manso, L.